Advisory: Give yourself extra time when travelling by car to Toronto General Hospital, Princess Margaret Cancer Centre, or Toronto Rehab University Centre. City of Toronto construction on University Ave. may cause delays.
At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
UHN's Peter Munk Cardiac Centre (PMCC) has taken another step forward in treating patients with advanced heart failure. PMCC staff successfully used a new kind of left ventricular assist device (LVAD) to treat a patient with advanced heart failure. The new device is longer-lasting than older generation LVADs and may eliminate the need for a second LVAD— a major drawback with the old technology.
The patient is 61-year-old Marva Lorde of Mississauga, who suffered a heart attack in 2007. She went through several treatments for heart failure (including a 10-day intensive care unit stay, angioplasty and pacemaker implantation), culminating in a heart attack in June 2008.
"I would have died in my sleep if the nurse hadn't checked my heart monitor," says Marva who is at home after receiving her LVAD earlier this summer. "Before the LVAD, I had trouble climbing the stairs to my bedroom, but now I'm back to my usual activities, including regular walks, and the stairs don't give me trouble anymore."
Marva's LVAD, known as the DuraHeart, is designed for long-term cardiac support and reduces the risk of complications.
The device's central pump is powered by magnetic levitation technology—meaning its moving parts are held in place with magnets instead of bearings. And that ultimately means less wear-and-tear on the device.
"With access to eight different types of cardiac assist devices, including the Duraheart, we have the most diverse array of circulatory support technology in Canada to best manage patients with end stage heart failure," says Dr. Vivek Rao, Surgical Director, Heart Transplant Program, PMCC.
Heart failure is the most common cause of hospitalization in North American adults and over 50,000 are treated for advanced heart failure annually. Transplantation is the only long-term treatment for end-stage heart failure patients and the long wait-times for a matching donor organ make it necessary to find other alternatives.Marva is currently on the heart transplant waiting list along with 36 other GTA residents. Her LVAD is her lifeline since her weak heart needs support until a new heart becomes available. This "bridge to life" is an innovative approach pioneered in Canada by Dr. Vivek Rao.
"Part of the centre's mandate is to evaluate new technologies such as the Duraheart to help determine which patients are best suited to a specific device," says Dr. Rao. His team has implanted approximately 70 LVADs since 2004, giving hope to many patients and families.